NPH 022
Alternative Names: NPH-022Latest Information Update: 28 May 2021
Price :
$50 *
At a glance
- Originator Nephraegis Therapeutics
- Class Eicosanoic acids; Epoxy compounds; Small molecules; Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute kidney injury
Most Recent Events
- 19 May 2021 NPH 022 is available for licensing as of 19 May 2021. https://www.nephraegis.com/
- 13 May 2021 Preclinical trials in Acute kidney injury (Prevention) in USA (IV) (Nephraegis website, May 2021)
- 13 May 2021 Preclinical trials in Acute kidney injury (Prevention) in USA (PO) (Nephraegis website, May 2021)